Friday, November 8, 2024
spot_img
More
    HomeLatest NewsShould Covishield Takers Be Concerned? AstraZeneca's Admission Raises Questions

    Should Covishield Takers Be Concerned? AstraZeneca’s Admission Raises Questions

    Reports of the Covid-19 vaccine Covishield being linked to heart attacks have raised widespread concern, especially after AstraZeneca, the company that sells it in India, testified before a UK court that the shot could induce a rare adverse effect called Thrombosis Thrombocytopenia Syndrome (TTS). This disorder is where blood clots form in odd locations throughout the body, and the quantity of platelets in the blood decreases.

    Covishield Causes Uncommon Side Effect

    Reports relating the Covid-19 vaccine Covishield to heart attacks have generated widespread worry, particularly after evidence from AstraZeneca, the firm that distributes it in India, in a UK court. According to AstraZeneca, the vaccination may cause an uncommon side effect known as Thrombosis Thrombocytopenia Syndrome (TTS). TTS is a condition defined by the production of blood clots in unusual places throughout the body, which is accompanied by a drop in platelet numbers. These clots frequently go to the heart, causing heart attacks, or to the brain, resulting in strokes. This is a common side effect of DNA vaccines, including Johnson & Johnson’s Janssen vaccine. 

    This impact has increased scrutiny of Covishield’s safety profile and raised concerns about immunisation’s dangers and benefits. It emphasises the significance of ongoing monitoring and evaluation of vaccine safety, particularly regarding rare but severe side effects. While the risk of TTS related to Covishield appears to be low, healthcare authorities and vaccine makers must offer honest and accurate information to the public about any possible dangers. This allows people to make more informed vaccination decisions and helps to retain trust in immunisation programs as efforts to prevent the Covid-19 outbreak continue.

    Over 90% of Indians Caccinated with Covishield

    It is anticipated that over 90% of Indians vaccinated against Covid-19 used Covishield. Since rumours regarding TTS became public, many doctors have received SOS calls from people who want to know how to protect themselves against a probable heart attack. Others have lost loved ones following vaccinations and are now linking their deaths to Covishield, threatening to sue the producers.

    However, doctors and epidemiologists warn that a ‘rare’ side effect is rare. Indeed, just seven to eight persons out of a million who receive the vaccine are expected to develop TTS. This comes to less than one individual in every 100,000 people. This is not the first time that digital misinformation about vaccines has sparked widespread alarm. During the pandemic, fact-checkers worked tirelessly to ensure that the public had access to credible and verifiable information about vaccine safety. 

    Anticipated Rate of TTS after Vaccine Exceedingly Low

    In this scenario, the anticipated rate of TTS after Covishield vaccination is exceedingly low, with only a small percentage of vaccinated people expected to be affected. This low incidence rate equates to less than one individual per 100,000 people, indicating the low risk associated with this consequence.

    Furthermore, observation concerning the overwhelming number of digital misinformation during the pandemic is noteworthy. Misinformation may create fear and confusion in the population, potentially harming vaccination efforts and public health programmes. Fact-checking programmes are essential in addressing misinformation and ensuring people can access trustworthy and verified vaccine safety and efficacy information.

    RELATED ARTICLES

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Most Popular

    spot_img
    spot_img